1-2 of 2
Francisco Mazorra, MD
Close
Sort by
Journal Articles

Risk Adapted-High Dose Therapies Modulate the Impact of Biological Classification in Diffuse Large B Cell Lymphoma Prognosis. Analysis of Biological Markers in Patients From Clinical Trials in Geltamo and Gotel Spanish Collaborative Groups.

Santiago Montes-Moreno, Ana Batlle, MD, Sonia Gonzalez de Villambrosia, MD, Beatriz Sanchez-Espiridión, PhD, Laura Cereceda, Eva González-Barca, Purroy Noelia, MD, Emilia Pardal, Elena Sebastian, Alejandro Martin, Carlos Grande, Francisco Mazorra, MD, Andrés Insunza, Antonio Rueda, MD, Marta Llanos, MD, Jose Gomez Codina, MD, Francisco Ramon Garcia Arroyo, MD, Dolores Caballero, MD, Eulogio Conde, Andrés Lopez, MD, Mariano Provencio, Miguel Piris, MD
Journal: Blood
Blood (2012) 120 (21): 2672.
https://doi.org/10.1182/blood.V120.21.2672.2672
Published: 2012
Journal Articles

Prognostic Value of cMYC Gene Abnormalities in Diffuse Large B Cell Lymphoma Treated with Chemo-Immunotherapy

Ana Batlle López, MD, PhD, Sonia Glez de Villambrosia, MD, Santiago Montes-Moreno, MD, Francisco Mazorra, MD, Andrés Insunza, MD, Anabel Sáez, MD, Carlos Montalban, MD, PhD, Lydia Sánchez, Juan F. Garcia, MD, Eva González-Barca, MD, A López, MD, MC Ruiz-Marcellan, MD, Manuela Mollejo, MD, Carlos Grande, MD, Cherie H. Dunphy, MD, ED His, MD, Ronald S. Go, MD, Carlo Visco, MD, Zijun Y. Xu-Monette, PhD, Ken H. Young, MD, Miguel Piris, MD, Eulogio Conde, Sr., MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2664.
https://doi.org/10.1182/blood.V118.21.2664.2664
Published: 2011